Evaluation of a spray-dried dispersion (SDD) formulation of MGCD265, a receptor tyrosine kinase (RTK) inhibitor, in a phase 1 study of patients (pts) with advanced solid tumors

被引：0
|
作者：
Sharma, Sunil
Shapiro, Geoffrey
Kollmannsberger, Christian K.
Christensen, James
Tassell, Vanessa Roberts
Faltaos, Demiana
Chao, Richard C.
Hurwitz, Herbert
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e14087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14087
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors
    Yutaka Fujiwara
    Hiroshi Nokihara
    Yasuhide Yamada
    Noboru Yamamoto
    Kuniko Sunami
    Hirofumi Utsumi
    Hiroya Asou
    Osamu TakahashI
    Ken Ogasawara
    Ivelina Gueorguieva
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 1143 - 1152
  • [32] A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors
    Schwartz, G. K.
    Robertson, S.
    Shen, A.
    Wang, E.
    Pace, L.
    Dials, H.
    Mendelson, D.
    Shannon, P.
    Gordon, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] A PHASE 1 STUDY OF IPI-926, AN INHIBITOR OF THE HEDGEHOG PATHWAY, IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC SOLID TUMORS
    Rudin, C. M.
    Weiss, G. J.
    Chang, A.
    Gettinger, S.
    Miller, W. H.
    Eigl, B.
    Savage, A.
    Loewen, G.
    Ross, R. W.
    Jimeno, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 164 - 164
  • [34] A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors
    Jazieh, Khalid
    Molina, Julian
    Allred, Jacob
    Yin, Jun
    Reid, Joel
    Goetz, Matthew
    Lim, Vun-Sin
    Kaufmann, Scott H.
    Adjei, Alex
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (02) : 307 - 314
  • [35] A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors
    Khalid Jazieh
    Julian Molina
    Jacob Allred
    Jun Yin
    Joel Reid
    Matthew Goetz
    Vun-Sin Lim
    Scott H. Kaufmann
    Alex Adjei
    Investigational New Drugs, 2019, 37 : 307 - 314
  • [36] A Phase I study of ZD6474, an oral VEGF receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Hurwitz, HI
    Eckhardt, SG
    Holden, SN
    Basser, R
    Deboer, R
    Rosenthal, M
    Rischin, D
    Swaisland, H
    Barge, A
    McKinley, M
    Wheeler, C
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3654S - 3654S
  • [37] Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
    Dees, E. Claire
    Infante, Jeffrey R.
    Cohen, Roger B.
    O'Neil, Bert H.
    Jones, Suzanne
    von Mehren, Margaret
    Danaee, Hadi
    Lee, Yih
    Ecsedy, Jeffrey
    Manfredi, Mark
    Galvin, Katherine
    Stringer, Bradley
    Liu, Hua
    Eton, Omar
    Fingert, Howard
    Burris, Howard
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) : 945 - 954
  • [38] Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
    E. Claire Dees
    Jeffrey R. Infante
    Roger B. Cohen
    Bert H. O’Neil
    Suzanne Jones
    Margaret von Mehren
    Hadi Danaee
    Yih Lee
    Jeffrey Ecsedy
    Mark Manfredi
    Katherine Galvin
    Bradley Stringer
    Hua Liu
    Omar Eton
    Howard Fingert
    Howard Burris
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 945 - 954
  • [39] A phase I study of the VEGF/PDGF receptor tyrosine kinase inhibitor AG-013736 in patients with advanced solid tumors: Safety, pharmacokinetics, and dceMRI.
    Herbst, R
    Rugo, H
    Liu, G
    Park, J
    Kies, M
    Pithavala, Y
    McShane, T
    Evelhoch, J
    Steinfeldt, H
    Reich, S
    Freddo, J
    Wilding, G
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6265S - 6265S
  • [40] Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumors
    Moore, Kathleen N.
    Jones, Suzanne Fields
    Kurkjian, Carla
    Arkenau, Hendrik-Tobias
    Infante, Jeffrey R.
    Pant, Shubham
    Burris, Howard A.
    McMeekin, D. Scott
    Gibbons, Jay
    Harrow, Kimberly
    Liang, Chris
    Ramsey, Sara
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345